Olvi-Vec

· Genelux Corporation

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Olvi-Vec, covering 2025-12-03 to 2026-06-12. Get the full timeline:

Most recent: Clinical Trial Results: Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer [Phase 1, Phase 2]